In conclusion, taking into account the limitations related to the sample sizes, which are not yet particularly large, the present study suggests that IL-1 inhibitors appear quite effective and safe for VEXAS patients, while IL-6 inhibition is useful, although more frequently leading to partial effectiveness. This evidence concerns the gene IL6 and VEXAS syndrome.